ERBB2 and breast cancer: Based on the worldwide clinical retrospective analysis, patients with luminal BC have the best outcomes with surgery, endocrine therapy, and chemotherapy; the HER2+ second and the patients with triple-negative BC (TNBC) usually have the worst prognosis due to limited therapeutic options (Waks and Winer, 2019).